- Home
- STEW vs KOD Comparison
STEW vs KOD Comparison
Compare STEW & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEW | KOD |
|---|---|---|
| Founded | 1972 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | STEW | KOD |
|---|---|---|
| Price | $18.38 | $23.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $28.29 |
| AVG Volume (30 Days) | 84.5K | ★ 709.8K |
| Earning Date | 01-01-0001 | 03-26-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.97 | $1.92 |
| 52 Week High | $14.94 | $31.18 |
Technical Indicators
Market Signals| Indicator | STEW | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 57.70 | 40.15 |
| Support Level | $18.05 | $20.88 |
| Resistance Level | $18.41 | $25.30 |
| Average True Range (ATR) | 0.19 | 2.02 |
| MACD | 0.05 | -0.60 |
| Stochastic Oscillator | 90.98 | 14.51 |
Price Performance
Historical ComparisonAbout STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.